EMs is a chronic systemic disease characterized by multiple clinical symptoms, including pelvic pain, dysmenorrhea, non-menstrual pelvic pain, and infertility.[29–32] As the 2 classic symptoms, persistent pelvic pain affects 40% to 50% of women and adolescents,[33] and 30% of patients with EMs have difficulty conceiving.[34] In the present study, a meta-analysis of RCTs reported that GZFL combined with DNG was more clinically effective than DNG alone in the therapy of EMs, and network pharmacology analysis revealed that this effect may be related to hormone receptor regulation. The gene discussed is NR4A1; the disease is eosinophilia-myalgia syndrome.